between LCH and melanoma when occurring together, with or without a shared BRAF pathogenic alteration. After surgery, the patient was treated with local radiotherapy. The oncology team planned on treating him with adjuvant immunotherapy, anti–PD-1, for
Search Results
Page:12
An Unexpected Diagnosis Uncovered by Quantitative Molecular Findings: A Case Report
Alessia Buglioni, Ruifeng Guo, Kandelaria M. Rumilla, Mark A. Edgar, Svetomir N. Markovic, and Gang Zheng
Preoperative and Postoperative Approaches to Gastroesophageal Cancer: What is All the Fuss About
Lucy X. Ma, Elan D. Panov, Michael J. Allen, Gail E. Darling, Jonathan C. Yeung, Carol J. Swallow, Savtaj S. Brar, Rebecca K. Wong, Patrick Veit-Haibach, Sangeetha N. Kalimuthu, Eric X. Chen, Raymond W. Jang, and Elena Elimova
became the standard of care for resectable esophageal cancer in North America. Adjuvant Immunotherapy Although the use of multimodality treatment has achieved incremental progress in improving outcomes in gastroesophageal cancers, up to half of
Management of Patients With Resectable and Metastatic Non–Small Cell Lung Cancer
Presented by: Jane Yanagawa and Gregory J. Riely
for adjuvant immunotherapy after lung resection for early-stage NSCLC. In the IMpower010 trial, 1,005 patients with completely resected stage IB–IIIA disease after adjuvant chemotherapy were randomly assigned to atezolizumab (up to 16 cycles or 1 year
The Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer
Laura M. Spring, Yael Bar, and Steven J. Isakoff
alone in a post hoc biomarkers analysis of the NeoTRIPaPDL1 study. 36 Nevertheless, identifying new predictive biomarkers for response to neoadjuvant immunotherapy remains an urgent need. Another key open question is whether adjuvant immunotherapy is
Immunotherapy-Based Neoadjuvant Treatment of Advanced Microsatellite Instability–High Gastric Cancer: A Case Series
Louisa Liu, Yanghee Woo, Massimo D’Apuzzo, Laleh Melstrom, Mustafa Raoof, Yu Liang, Michelle Afkhami, Stanley R. Hamilton, and Joseph Chao
of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease . Cancer Discov 2016 ; 6 : 1382 – 1399 . 27663893 10.1158/2159-8290.CD-16-0577 15. O’Donnell JS , Hoefsmit EP , Smyth MJ , The promise of
Regional Radiation Therapy Impacts Outcome for Node-Positive Cutaneous Melanoma
Tobin Strom, Javier F. Torres-Roca, Akash Parekh, Arash O. Naghavi, Jimmy J. Caudell, Daniel E. Oliver, Jane L. Messina, Nikhil I. Khushalani, Jonathan S. Zager, Amod Sarnaik, James J. Mulé, Andy M. Trotti, Steven A. Eschrich, Vernon K. Sondak, and Louis B. Harrison
.277–2.399; P <.001), nodal size >2 cm (HR, 1.405; 95% CI, 1.045–1.889; P =.02), and adjuvant immunotherapy (to be reported separately). OS by RSI Status To assess whether a gene signature of radiosensitivity could help identify which patients might
On the Verge: Immunotherapy for Colorectal Carcinoma
David Y. Oh, Alan P. Venook, and Lawrence Fong
adjuvant immunotherapy with BCG and neuraminidase-treated autologous tumour cells in large bowel cancer . J Surg Oncol 1989 ; 40 : 34 – 37 . 18. Hoover HC Jr Brandhorst JS Peters LC . Adjuvant active specific immunotherapy for human
Page:12
